Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

2019/11/01 by Harry G M Heijerman, Edward F McKone, Edward F. McKone +87 · 3 citations
Medicine · Social Sciences · #Cystic Fibrosis Research Advances #Delphi Technique in Research #Neonatal Respiratory Health Research

paper · pdf · doi:10.1016/s0140-6736(19)32597-8

crossref issued 2019/11/01 · crossref published 2019/11/01 · crossref published-print 2019/11/01 · openalex publication_date 2019/11/01 · crossref created 2019/11/01 · crossref deposited 2025/09/26 · openalex created_date 2025/10/10 · crossref indexed 2026/08/05 · openalex updated_date 2026/08/05

Citations

• Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations
• Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or twoF508delalleles
• Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele

Cited by

• A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele
• Chronic rhinosinusitis in cystic fibrosis: a review of therapeutic options
• Elexacaftor/tezacaftor/ivacaftor [wikipedia]